Wegovy’s Potential Heart Benefit Factors Into Coverage Decisions

Novo Nordisk’s recent announcement that its blockbuster obesity drug Wegovy reduced heart disease risk is prompting employers to look into covering pricey weight-loss drugs.

The National Alliance of Healthcare Purchaser Coalitions, which represents employer and union health-care coalitions that spend over $400 billion a year covering more than 45 million Americans, expects to issue best practice guidance by the end of the year on covering Wegovy and other weight-loss drugs, President and CEO Michael Thompson said in an interview.

Whether and how to cover Wegovy and other weight-loss drugs “is one of the more complex issues for people who run ...